Personalized EEG-Guided Transcranial Magnetic Stimulation for Post-Traumatic Stress Disorder in Veterans: 10-Session Randomized, Sham-Controlled Study

Introduction: Post-traumatic stress disorder (PTSD) is prevalent and disabling among veterans, in whom standard therapies show limited efficacy. PTSD is associated with disrupted cortical oscillations and altered default mode network connectivity. Magnetic EEG-Guided Resonance Therapy (MeRT) is repetitive transcranial magnetic stimulation (rTMS) with pulse rate matched to each patient’s algorithmically EEG-derived frequency (8 to 13 Hz), recently FDA-cleared for PTSD. We evaluated MeRT-guided rTMS versus sham in veterans with PTSD with 10 sessions of treatment.

Methods: Veterans aged 18 to 55 with primary PTSD (CAPS, DSM-IV) and PCL-Military (PCL-M) above 45 were randomized at one site to active MeRT-guided rTMS or sham for two weeks. Resting eyes-closed 19-channel EEG informed the MeRT algorithm, which set each participant’s stimulation pulse rate. Active stimulation targeted medial prefrontal cortex (Fz) at 80% motor threshold in 6-second trains, 54-second intervals, 30 minutes daily, 5 days weekly (10 sessions), with a figure-of-eight double-blind MagVenture coil. Active participants received two additional weeks (20 sessions total), sham did not continue. PCL-M, PSQI-A, and Hamilton Depression Rating Scale (HAM-D) were assessed at baseline and week two, with PCL-M repeated at week four in active participants. Between-group deltas used Mann-Whitney U with Holm-Bonferroni correction. Clinically meaningful response (10-point or greater PCL-M reduction) used chi-square.

Results: Seventy-three participants were analyzed (36 active, 37 sham) with no baseline differences. Individualized frequencies ranged 8.8 to 12.3 Hz (mean 10.3, SD 0.76). At week two, active PCL-M fell 33.9% (delta 22.4, SD 14.9) versus 24.0% in sham (delta 15.9, SD 16.7), a significant difference (corrected p = 0.049, r = -0.31). More active participants achieved clinically meaningful improvement (28/36, 78%) than sham (18/37, 49%, chi-square = 6.6, p = 0.01). All active participants scored above the clinically suggestive PCL-M cutoff of 50 at baseline, and 25 (69%) fell below this threshold at week two. Sleep improved more with active treatment (PSQI-A -43.9% versus -16.4%, corrected p = 0.030, r = -0.35). HAM-D did not differ (p = 0.130). With extended treatment, active PCL-M fell to 33.2 (SD 12.2) at week four, a 49.2% reduction from baseline (uncontrolled). No severe adverse events occurred. Headache was most common and resolved within one week.

Conclusion: Ten sessions of MeRT-guided rTMS produced significantly greater reductions in PTSD severity and sleep disturbance than sham in veterans, with a favorable safety profile. Extension to 20 sessions was associated with further symptom reduction, suggesting a possible dose-response, though the absence of a four-week sham comparator precludes controlled inference. The small sample and sham blinding remain limitations. These findings support individualized, electrophysiology-guided neuromodulation, now FDA-cleared for PTSD, as a rapid non-pharmacologic option warranting larger controlled trials with longer follow-up.